{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:46:13Z","timestamp":1789674373035,"version":"4.0.1"},"reference-count":28,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science KAKENHI","doi-asserted-by":"crossref","award":["JP20K16076"],"award-info":[{"award-number":["JP20K16076"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>Chemotherapy for breast cancer includes pertuzumab and trastuzumab regimens with docetaxel (PHD) or paclitaxel (PHP). Current approaches for using supportive care drugs to manage the side effects of PHD and PHP are unclear. Here, we investigated the occurrence of side effects before and after supportive care medications were modified by discontinuing antipyretic analgesics. We retrospectively analyzed adverse events that occurred within 24 h of treating 76 patients with PHD or PHP. The frequencies of adverse effects in the groups before and after modification did not differ significantly (45.5% [15\/33] and 44.2% [19\/43], respectively). Severity also did not significantly differ between the groups. Therefore, discontinuing antipyretic analgesics as supportive care drugs had little effect on the frequency of side effects. Symptoms of feeling hot, pyrexic, and flushed were frequent, and their severity increased in the group after the support drugs were modified. Discontinuation of supportive care medications, including antipyretic analgesics, might affect the severity of certain symptoms and lead to the development of side effects that require medical intervention. Overall, our findings indicate the need to consider premedication with antipyretic analgesics, including further analysis of the risk factors that can predict symptoms.<\/jats:p>","DOI":"10.3390\/pharmacy13060168","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T15:38:09Z","timestamp":1763393889000},"page":"168","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of Modifying Supportive Care Medications in Combination Therapy with Pertuzumab, Trastuzumab, and Taxane Anticancer Drugs"],"prefix":"10.3390","volume":"13","author":[{"given":"Mina","family":"Takagi","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, The University of Osaka, 1-6 Yamadaoka, Suita 565-0871, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Maeda","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, The University of Osaka, 1-6 Yamadaoka, Suita 565-0871, Osaka, Japan"},{"name":"Department of Pharmacy, The University of Osaka Hospital, 2-15 Yamadaoka, Suita 565-0871, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4408-7019","authenticated-orcid":false,"given":"Makiko","family":"Maeda","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, The University of Osaka, 1-6 Yamadaoka, Suita 565-0871, Osaka, Japan"},{"name":"Laboratory of Molecular Pharmaceutical Science, Graduate School of Medicine, The University of Osaka, 2-2 Yamadaoka, Suita 565-0871, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Fujio","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, The University of Osaka, 1-6 Yamadaoka, Suita 565-0871, Osaka, Japan"},{"name":"Laboratory of Clinical Science and Biomedicine, Graduate School of Pharmaceutical Sciences, The University of Osaka, 1-6 Yamadaoka, Suita 565-0871, Osaka, Japan"},{"name":"Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, The University of Osaka, 1-1 Yamdaoka, Suita 565-0871, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8218-8809","authenticated-orcid":false,"given":"Sachiko","family":"Hirobe","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, The University of Osaka, 1-6 Yamadaoka, Suita 565-0871, Osaka, Japan"},{"name":"Department of Pharmacy, The University of Osaka Hospital, 2-15 Yamadaoka, Suita 565-0871, Osaka, Japan"},{"name":"Laboratory of Molecular Pharmaceutical Science, Graduate School of Medicine, The University of Osaka, 2-2 Yamadaoka, Suita 565-0871, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1634\/theoncologist.2008-0012","article-title":"Managing premedications and the risk for reactions to infusional monoclonal antibody therapy","volume":"13","author":"Chung","year":"2008","journal-title":"Oncologist"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","article-title":"Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease","volume":"17","author":"Cobleigh","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000055403","article-title":"Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer","volume":"61","year":"2001","journal-title":"Oncology"},{"key":"ref_4","first-page":"iv100","article-title":"ESMO Guidelines Committee. Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines","volume":"28","author":"Blasco","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1248\/bpb.b19-00876","article-title":"Effects of diluent volume and administration time on the incidence of anaphylaxis following docetaxel therapy in breast cancer","volume":"43","author":"Ishida","year":"2020","journal-title":"Biol. Pharm. Bull."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e630","DOI":"10.3747\/co.21.1966","article-title":"Comit\u00e9 de l\u2019\u00e9volution des pratiques en oncologie. Management of hypersensitivity to platinum- and taxane-based chemotherapy: Cepo review and clinical recommendations","volume":"21","author":"Boulanger","year":"2014","journal-title":"Curr. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/oxfordjournals.annonc.a058903","article-title":"Paclitaxel (Taxol) and docetaxel (Taxotere): Not simply two of a kind","volume":"5","author":"Verweij","year":"1994","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1111\/bcp.15675","article-title":"Preventive effect of dexamethasone premedication on the development of infusion-related reaction in breast cancer patients receiving trastuzumab","volume":"89","author":"Goto","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.9734\/jammr\/2021\/v33i2231156","article-title":"The preferred premedication order to prevent infusion reactions in patients with breast cancer receiving pertuzumab plus trastuzumab and docetaxel","volume":"33","author":"Nakagaki","year":"2021","journal-title":"J. Adv. Med. Med. Res."},{"key":"ref_10","first-page":"776","article-title":"Preventive effect of infusion reaction by changing the administration order of dexamethasone in preoperative and postoperative adjuvant chemotherapy in pertuzumab, trastuzumab, and docetaxel combination therapy","volume":"58","author":"Inada","year":"2022","journal-title":"J. Jpn. Soc. Hosp. Pharm."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clbc.2011.10.002","article-title":"Randomized Phase II study of primary systemic chemotherapy and trastuzumab for operable HER2 positive breast cancer","volume":"12","author":"Nakamura","year":"2012","journal-title":"Clin. Breast Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1634\/theoncologist.2013-0286","article-title":"Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving trastuzumab","volume":"19","author":"Thompson","year":"2014","journal-title":"Oncologist"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/BF02967530","article-title":"Compassionate use of humanized anti-HER2\/neu protein, trastuzumab for metastatic breast cancer in Japan","volume":"8","author":"Tokuda","year":"2001","journal-title":"Breast Cancer"},{"key":"ref_14","first-page":"1298","article-title":"Survey of risk factors affecting infusion reaction in patients receiving trastuzumab monotherapy","volume":"58","author":"Shimada","year":"2022","journal-title":"J. Jpn. Soc. Hosp. Pharm."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/annonc\/mdx494","article-title":"De-escalation strategies in HER2-positive early breast cancer (EBC): Final analysis of the WSG-ADAPT HER2+\/HR- phase II trial: Efficacy, safety, and predictive markers for 12\u2009weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab \u00b1 weekly paclitaxel","volume":"28","author":"Nitz","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1248\/bpb.b23-00123","article-title":"Risk factors for infusion reactions in patients with breast cancer administered trastuzumab therapy","volume":"46","author":"Tabuchi","year":"2023","journal-title":"Biol. Pharm. Bull."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S1081-1206(10)60078-6","article-title":"Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents","volume":"102","author":"Lee","year":"2009","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4168\/aair.2024.16.2.142","article-title":"Hypersensitivity reactions to taxanes: A multicenter study for outcomes and safety of rapid drug desensitization","volume":"16","author":"Unutmaz","year":"2024","journal-title":"Allergy Asthma Immunol. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"116","DOI":"10.5152\/eurasianjmed.2018.0010","article-title":"Effects of nonsteroidal anti-inflammatory drugs at the molecular level","volume":"50","author":"Gunaydin","year":"2018","journal-title":"Eurasian J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e00014-21","DOI":"10.1128\/JVI.00014-21","article-title":"Non-steroidal anti-inflammatory drugs dampen the cytokine and antibody response to SARS-CoV-2 infection","volume":"95","author":"Chen","year":"2021","journal-title":"J. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3892\/etm.2021.10381","article-title":"Hypersensitivity reactions to monoclonal antibodies: Classification and treatment approach (Review)","volume":"22","author":"Pintea","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)","volume":"94","author":"Winkler","year":"1999","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ebiom.2018.12.051","article-title":"Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study","volume":"40","author":"Hershberger","year":"2019","journal-title":"EBiomedicine"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(17)30434-5","article-title":"CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: A randomised, double-blind, active-controlled, phase 3 equivalence trial","volume":"18","author":"Stebbing","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41416-018-0340-2","article-title":"PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: A randomised, double-blind study","volume":"120","author":"Pegram","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1470-2045(20)30536-2","article-title":"Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): A randomised, open-label, multicentre, non-inferiority, phase 3 study","volume":"22","author":"Tan","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"525A","DOI":"10.1016\/j.chest.2016.08.539","article-title":"Delayed Trastuzumb (Herceptin)-Related ARDS","volume":"150","author":"Shrimp","year":"2016","journal-title":"Chest"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40259-013-0066-x","article-title":"Drug desensitization in the management of hypersensitivity reactions to monoclonal antibodies and chemotherapy","volume":"28","author":"Mezzano","year":"2014","journal-title":"BioDrugs"}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/13\/6\/168\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T05:22:38Z","timestamp":1763529758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/13\/6\/168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["pharmacy13060168"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy13060168","relation":{},"ISSN":["2226-4787"],"issn-type":[{"value":"2226-4787","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]}}}